Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Toxicities of MM drug treatments

Ravi Vij • 15 Sep 2019
IMW 2019
Multiple Myeloma Bortezomib Carfilzomib Lenalidomide Olanzopine Panobinostat Pomalidomide Selinexor Thalidomide

Ravi Vij, MD, MBA Washington University Medical School, St Louis, MO, discusses toxicities of multiple myeloma (MM) drug treatments and managing these side-effects, speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Ravi Vij

2:48
MRD status by mass spectrometry with EasyM predicts outcomes following autoSCT in multiple myeloma
Ravi Vij • 11 Dec 2023
2:26
Lenalidomide as post-autoSCT maintenance therapy for multiple myeloma
Ravi Vij • 11 Dec 2023
3:23
Updated safety and efficacy results of Abbv-383, a novel BsAb, in patients with R/R multiple myeloma
Ravi Vij • 11 Dec 2023
2:35
Resistance to immunotherapy in multiple myeloma: mechanisms & monitoring
Ravi Vij • 12 Dec 2022

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals